scientif
research
respons
public
health
crisi
occur
rel
case
rapid
sequenc
sever
acut
respiratori
syndrom
sar
viru
unfortun
mani
condit
caus
death
sick
lowincom
countri
larg
neglect
pharmaceut
industri
although
three
preval
infecti
tuberculosi
kill
million
year
develop
world
subject
privatesector
research
develop
r
anoth
sens
also
suffer
well
serv
basic
research
translat
quickli
enough
effect
product
strong
medicin
creat
incent
pharmaceut
research
neglect
diseas
michael
kremer
rachel
glennerst
argu
vaccin
offer
best
hope
conquer
mani
diseas
vaccin
intern
public
good
scientif
advanc
creat
vaccin
r
consequ
public
health
benefit
spill
broader
societi
realiti
howev
r
medicin
includ
vaccin
treat
diseas
must
heavili
subsid
variou
way
mani
differ
r
incent
system
suggest
push
programm
provid
impetu
public
privat
research
input
offer
academ
grant
support
public
laboratori
equiti
invest
product
develop
tax
credit
r
invest
pull
incent
increas
research
output
reward
develop
specif
product
central
argument
strong
medicin
effect
form
incent
creat
vaccin
diseas
affect
develop
world
pull
commit
sponsor
fulli
partial
financ
vaccin
purchas
even
develop
author
advoc
fund
author
prescrib
vaccin
effect
price
make
copay
return
invest
wish
develop
vaccin
free
ex
ant
payforplay
activ
call
advanc
purchas
commit
apc
principl
design
attract
earlystag
equiti
ventur
capit
financ
eventu
repay
public
coffer
success
vaccin
produc
kremer
articul
advoc
mani
year
first
three
chapter
strong
medicin
form
overview
diseas
develop
countri
lack
r
everi
year
us
billion
spent
worldwid
health
r
public
privat
sector
howev
money
devot
health
problem
less
world
popul
chapter
discuss
mani
market
distort
limit
r
neglect
diseas
pharmaceut
firm
fear
abl
sell
medicin
price
cover
cost
r
expertis
infrastructur
manag
almost
entir
privat
sector
concentr
west
direct
toward
profit
drug
prosper
market
author
describ
advantag
disadvantag
push
pull
incent
sanguin
push
programm
particularli
publicli
fund
one
latestag
research
remain
chapter
apc
pull
programm
discuss
detail
note
firm
would
perform
r
apc
reason
confid
prospect
success
strong
medicin
argu
apc
may
best
suit
latestag
vaccin
develop
strong
medicin
make
suggest
read
power
suggest
go
far
apc
yet
untest
expens
experi
inde
funder
govern
embrac
concept
without
critic
analysi
model
present
support
apc
strong
medicin
seem
overli
simplist
suspect
economist
could
comprehens
evalu
apc
deal
realworld
highli
complex
situat
model
develop
strong
medicin
avoid
complex
perhap
slim
volum
inevit
reader
take
apc
faith
instanc
access
vaccin
r
technolog
depend
firm
scientist
also
firm
ownership
intellectu
properti
ip
strong
medicin
appear
unrealist
model
ip
right
alway
function
perfectli
asymmetr
inform
problem
financi
constraint
ip
ownership
strateg
behaviour
sort
author
model
appar
assum
one
vaccin
r
entiti
held
back
player
ownership
ip
inde
risk
relat
actual
potenti
ownership
ip
hold
back
posit
firm
likelihood
success
anoth
reason
apc
may
poor
incent
earlystag
r
apc
must
one
mani
creativ
idea
consid
instanc
sever
expert
stakehold
propos
new
global
treati
support
medic
r
see
wwwcptechorg
provid
new
oblig
econom
incent
invest
research
project
collabor
inform
exchang
softwar
industri
suggest
anoth
avenu
promot
develop
new
medicin
open
environ
conduc
free
dissemin
basic
research
result
biomed
r
system
independ
effort
develop
end
user
come
togeth
part
nonintegr
innov
process
propel
organiz
chang
promot
divis
labour
perhap
system
would
suitabl
earli
stage
discoveri
apc
would
use
drive
develop
final
product
strong
medicin
read
wide
present
creativ
financ
model
r
could
extrem
import
apc
howev
panacea
probabl
go
difficult
make
earlystag
apc
work
burden
proof
unresolv
book
rest
author
optimist
messag
strong
medicin
occlud
vision
apc
solut
lack
biomed
innov
neglect
popul
avenu
explor
critic
review
